<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;ff=20240321021056&amp;v=2.18.0.post9+e462414&amp;utm_campaign=pubmed-2
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;ff=20240321021056&amp;v=2.18.0.post9+e462414&amp;utm_campaign=pubmed-2" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Thu, 21 Mar 2024 06:10:57 +0000</lastbuilddate>
<pubDate>Wed, 20 Mar 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Reply: Aging in Patients With Fontan Circulation: Raison d'être of Right Ventricle</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38508853/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240321021056&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Mar 26;83(12):e119. doi: 10.1016/j.jacc.2024.01.022.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38508853/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240321021056&v=2.18.0.post9+e462414">38508853</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.01.022>10.1016/j.jacc.2024.01.022</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38508853</guid>
<pubDate>Wed, 20 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Rani Zierath</dc:creator>
<dc:creator>Amil M Shah</dc:creator>
<dc:date>2024-03-20</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: Aging in Patients With Fontan Circulation: Raison d'être of Right Ventricle</dc:title>
<dc:identifier>pmid:38508853</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.01.022</dc:identifier>
</item>
<item>
<title>Aging in Patients With Fontan Circulation: Raison d'être of Right Ventricle</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38508852/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240321021056&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Mar 26;83(12):e117. doi: 10.1016/j.jacc.2023.12.035.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38508852/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240321021056&v=2.18.0.post9+e462414">38508852</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.12.035>10.1016/j.jacc.2023.12.035</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38508852</guid>
<pubDate>Wed, 20 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Tomoaki Murakami</dc:creator>
<dc:date>2024-03-20</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Aging in Patients With Fontan Circulation: Raison d'être of Right Ventricle</dc:title>
<dc:identifier>pmid:38508852</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.12.035</dc:identifier>
</item>
<item>
<title>Accuracy of Wearable Heart Rate Monitors During Exercise in Sinus Rhythm and Atrial Fibrillation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38508851/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240321021056&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Mar 26;83(12):1177-1179. doi: 10.1016/j.jacc.2024.01.024.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38508851/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240321021056&v=2.18.0.post9+e462414">38508851</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.01.024>10.1016/j.jacc.2024.01.024</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38508851</guid>
<pubDate>Wed, 20 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Ryan Quinn</dc:creator>
<dc:creator>Nathan Leader</dc:creator>
<dc:creator>Gerald Lebovic</dc:creator>
<dc:creator>Chi-Ming Chow</dc:creator>
<dc:creator>Paul Dorian</dc:creator>
<dc:date>2024-03-20</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Accuracy of Wearable Heart Rate Monitors During Exercise in Sinus Rhythm and Atrial Fibrillation</dc:title>
<dc:identifier>pmid:38508851</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.01.024</dc:identifier>
</item>
<item>
<title>Genetic Factors Altering Immune Responses in Atrial Fibrillation: JACC Review Topic of the Week</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38508850/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240321021056&amp;v=2.18.0.post9+e462414
      <description>Atrial fibrillation (AF) is the most common cardiac arrhythmia worldwide and is associated with a range of adverse clinical outcomes. Accumulating evidence points to inflammatory processes resulting from innate immune responses as a cornerstone in AF pathogenesis. Genetic and epigenetic factors affecting leukocytes have been identified as key modulators of the inflammatory response. Inherited variants in genes encoding proteins involved in the innate immune response have been associated with...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Mar 26;83(12):1163-1176. doi: 10.1016/j.jacc.2023.12.034.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Atrial fibrillation (AF) is the most common cardiac arrhythmia worldwide and is associated with a range of adverse clinical outcomes. Accumulating evidence points to inflammatory processes resulting from innate immune responses as a cornerstone in AF pathogenesis. Genetic and epigenetic factors affecting leukocytes have been identified as key modulators of the inflammatory response. Inherited variants in genes encoding proteins involved in the innate immune response have been associated with increased risk for AF recurrence and stroke in AF patients. Furthermore, acquired somatic mutations associated with clonal hematopoiesis of indeterminate potential, leukocyte telomere shortening, and epigenetic age acceleration contribute to increased AF risk. In individuals carrying clonal hematopoiesis of indeterminate potential, myocardial monocyte-derived macrophage shift toward a proinflammatory phenotype may precipitate AF. Further studies are needed to better understand the role of genetic regulation of the native immune response in atrial arrhythmogenesis and its therapeutic potential as a target for personalized medicine.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38508850/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240321021056&v=2.18.0.post9+e462414">38508850</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.12.034>10.1016/j.jacc.2023.12.034</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38508850</guid>
<pubDate>Wed, 20 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Sandro Ninni</dc:creator>
<dc:creator>David Dombrowicz</dc:creator>
<dc:creator>Menno de Winther</dc:creator>
<dc:creator>Bart Staels</dc:creator>
<dc:creator>David Montaigne</dc:creator>
<dc:creator>Stanley Nattel</dc:creator>
<dc:date>2024-03-20</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Genetic Factors Altering Immune Responses in Atrial Fibrillation: JACC Review Topic of the Week</dc:title>
<dc:identifier>pmid:38508850</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.12.034</dc:identifier>
</item>
<item>
<title>Frailty and Cognitive Function in Aging Adults With Congenital Heart Disease: A Lifetime of Limitations?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38508849/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240321021056&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Mar 26;83(12):1160-1162. doi: 10.1016/j.jacc.2024.02.006.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38508849/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240321021056&v=2.18.0.post9+e462414">38508849</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.02.006>10.1016/j.jacc.2024.02.006</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38508849</guid>
<pubDate>Wed, 20 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Matthew R Carazo</dc:creator>
<dc:date>2024-03-20</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Frailty and Cognitive Function in Aging Adults With Congenital Heart Disease: A Lifetime of Limitations?</dc:title>
<dc:identifier>pmid:38508849</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.02.006</dc:identifier>
</item>
<item>
<title>Frailty and Cognitive Function in Middle-Aged and Older Adults With Congenital Heart Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38508848/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240321021056&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Approximately one-half of included patients were (pre-)frail, and more than one-third experienced cognitive impairment. Frailty and cognitive dysfunction were identified in patients with mild CHD, indicating that these concerns extend beyond severe CHD. Assessing frailty and cognition routinely could offer valuable insights into this aging population.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Mar 26;83(12):1149-1159. doi: 10.1016/j.jacc.2024.01.021.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Life expectancy of patients with congenital heart disease (CHD) has increased rapidly, resulting in a growing and aging population. Recent studies have shown that older people with CHD have higher morbidity, health care use, and mortality. To maintain longevity and quality of life, understanding their evolving medical and psychosocial challenges is essential.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The authors describe the frailty and cognitive profile of middle-aged and older adults with CHD to identify predictor variables and to explore the relationship with hospital admissions and outpatient visits.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Using a cross-sectional, multicentric design, we included 814 patients aged ≥40 years from 11 countries. Frailty phenotype was determined using the Fried method. Cognitive function was assessed by the Montreal Cognitive Assessment.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In this sample, 52.3% of patients were assessed as robust, 41.9% as prefrail, and 5.8% as frail; 38.8% had cognitive dysfunction. Multinomial regression showed that frailty was associated with older age, female sex, higher physiologic class, and comorbidities. Counterintuitively, patients with mild heart defects were more likely than those with complex lesions to be prefrail. Patients from middle-income countries displayed more prefrailty than those from higher-income countries. Logistic regression demonstrated that cognitive dysfunction was related to older age, comorbidities, and lower country-level income.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Approximately one-half of included patients were (pre-)frail, and more than one-third experienced cognitive impairment. Frailty and cognitive dysfunction were identified in patients with mild CHD, indicating that these concerns extend beyond severe CHD. Assessing frailty and cognition routinely could offer valuable insights into this aging population.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38508848/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240321021056&v=2.18.0.post9+e462414">38508848</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.01.021>10.1016/j.jacc.2024.01.021</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38508848</guid>
<pubDate>Wed, 20 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Bo Daelman</dc:creator>
<dc:creator>Liesbet Van Bulck</dc:creator>
<dc:creator>Koen Luyckx</dc:creator>
<dc:creator>Adrienne H Kovacs</dc:creator>
<dc:creator>Alexander Van De Bruaene</dc:creator>
<dc:creator>Magalie Ladouceur</dc:creator>
<dc:creator>Hsiao-Ling Yang</dc:creator>
<dc:creator>Ju Ryoung Moon</dc:creator>
<dc:creator>André Schmidt</dc:creator>
<dc:creator>Birgitte Lykkeberg</dc:creator>
<dc:creator>Edward Callus</dc:creator>
<dc:creator>Michèle de Hosson</dc:creator>
<dc:creator>Camilla Sandberg</dc:creator>
<dc:creator>Bengt Johansson</dc:creator>
<dc:creator>Joanna Hlebowicz</dc:creator>
<dc:creator>Maria Emília Areias</dc:creator>
<dc:creator>Pascal Amedro</dc:creator>
<dc:creator>Louise Coats</dc:creator>
<dc:creator>Zacharias Mandalenakis</dc:creator>
<dc:creator>Anna Kaneva</dc:creator>
<dc:creator>Philip Moons</dc:creator>
<dc:creator>Eva Goossens</dc:creator>
<dc:creator>APPROACH-IS II consortium</dc:creator>
<dc:creator>International Society for Adult Congenital Heart Disease</dc:creator>
<dc:date>2024-03-20</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Frailty and Cognitive Function in Middle-Aged and Older Adults With Congenital Heart Disease</dc:title>
<dc:identifier>pmid:38508848</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.01.021</dc:identifier>
</item>
<item>
<title>New Findings on Ascending Aortic Dilation in Coarctation of the Aorta: Expanding Perspectives</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38508847/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240321021056&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Mar 26;83(12):1147-1148. doi: 10.1016/j.jacc.2024.02.011.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38508847/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240321021056&v=2.18.0.post9+e462414">38508847</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.02.011>10.1016/j.jacc.2024.02.011</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38508847</guid>
<pubDate>Wed, 20 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Daniel Rinnström</dc:creator>
<dc:creator>Bengt Johansson</dc:creator>
<dc:date>2024-03-20</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>New Findings on Ascending Aortic Dilation in Coarctation of the Aorta: Expanding Perspectives</dc:title>
<dc:identifier>pmid:38508847</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.02.011</dc:identifier>
</item>
<item>
<title>Coarctation of Aorta With Tricuspid Aortic Valve Is Not Associated With Ascending Aortic Aneurysm</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38508846/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240321021056&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: These findings suggest that BAV (and not COA) was associated with ascending thoracic aorta dimensions, and that patients with COA+TAV were not at a greater risk of developing ascending aortic aneurysms as compared with patients without SHD.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Mar 26;83(12):1136-1146. doi: 10.1016/j.jacc.2024.01.026.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Aortic aneurysm is common in patients with coarctation of aorta (COA), but it is unclear whether the risk of aortic aneurysms is due to COA or related to the presence of other risk factors such as bicuspid aortic valve (BAV) and hypertension.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The purpose of this study was to assess the relationship among COA, BAV, and thoracic aortic aneurysms.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A total of 867 patients with COA (COA group) were matched 1:1:1 to 867 patients with isolated BAV (BAV group) and 867 patients without structural heart disease (SHD) (no-SHD group). The COA group was further subdivided into a COA+BAV subgroup (n = 304 [35%]), and COA with tricuspid aortic valve (TAV) (COA+TAV subgroup [n = 563 (65%)]). Aortic dimensions were assessed at baseline and at 3, 5, and 7 years.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Compared with the no-SHD group, the COA+BAV subgroup had larger aortic root diameter (37 mm [Q1-Q3: 30-43 mm] vs 32 mm [Q1-Q3: 27-35 mm]; P &lt; 0.001) and mid ascending aorta dimeter (34 mm [Q1-Q3: 29-40 mm] vs 28 mm [Q1-Q3: 24-31 mm]; P = 0.008). Similarly, the BAV group had larger aortic root diameter (37 mm [Q1-Q3: 30-42 mm] vs 32 mm [Q1-Q3: 27-35 mm]; P &lt; 0.001), and mid ascending aorta dimeter (35 mm [Q1-Q3: 30-40 mm] vs 28 mm [Q1-Q3: 24-31 mm]; P &lt; 0.001). Compared with the COA+TAV subgroup, the COA+BAV subgroup and BAV group were associated with larger aortic root and mid ascending aorta diameter at baseline and follow-up. The risk of acute aortic complications was low in all groups.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: These findings suggest that BAV (and not COA) was associated with ascending thoracic aorta dimensions, and that patients with COA+TAV were not at a greater risk of developing ascending aortic aneurysms as compared with patients without SHD.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38508846/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240321021056&v=2.18.0.post9+e462414">38508846</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.01.026>10.1016/j.jacc.2024.01.026</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38508846</guid>
<pubDate>Wed, 20 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Alexander C Egbe</dc:creator>
<dc:creator>William R Miranda</dc:creator>
<dc:creator>Omar Abozied</dc:creator>
<dc:creator>C Charles Jain</dc:creator>
<dc:creator>Luke J Burchill</dc:creator>
<dc:creator>Snigdha Karnakoti</dc:creator>
<dc:creator>Marwan H Ahmed</dc:creator>
<dc:creator>Christopher J Francois</dc:creator>
<dc:creator>Heidi M Connolly</dc:creator>
<dc:date>2024-03-20</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Coarctation of Aorta With Tricuspid Aortic Valve Is Not Associated With Ascending Aortic Aneurysm</dc:title>
<dc:identifier>pmid:38508846</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.01.026</dc:identifier>
</item>
<item>
<title>Pooling the NT-proBNP Benefits of ARNI: Fret the Index Hospitalization No More</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38508845/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240321021056&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Mar 26;83(12):1133-1135. doi: 10.1016/j.jacc.2024.02.001.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38508845/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240321021056&v=2.18.0.post9+e462414">38508845</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.02.001>10.1016/j.jacc.2024.02.001</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38508845</guid>
<pubDate>Wed, 20 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Bassam Atallah</dc:creator>
<dc:creator>Hussam H Ghalib</dc:creator>
<dc:date>2024-03-20</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Pooling the NT-proBNP Benefits of ARNI: Fret the Index Hospitalization No More</dc:title>
<dc:identifier>pmid:38508845</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.02.001</dc:identifier>
</item>
<item>
<title>Sacubitril/Valsartan in Patients Hospitalized With Decompensated Heart Failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38508844/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240321021056&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In patients stabilized after WHF, sacubitril/valsartan led to a greater reduction in plasma NT-proBNP and improved clinical outcome compared with control therapy, in particular across the spectrum of EF ≤60%. (Comparison of Sacubitril/Valsartan Versus Enalapril on Effect of NT-proBNP in Patients Stabilized From an Acute Heart Failure Episode [PIONEER-HF]; NCT02554890; Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event [HFpEF Decompensation] Who Have...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Mar 26;83(12):1123-1132. doi: 10.1016/j.jacc.2024.01.027.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The efficacy and safety of sacubitril/valsartan in patients hospitalized with heart failure (HF) across the spectrum of left ventricular ejection fraction (EF) has not been described.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: Data from randomized trials of sacubitril/valsartan in HF patients with EF ≤40% (PIONEER-HF [Comparison of Sacubitril/Valsartan Versus Enalapril on Effect of NT-proBNP in Patients Stabilized From an Acute Heart Failure Episode] trial) and >;40% (PARAGLIDE-HF [Prospective comparison of ARNI with ARB Given following stabiLization In DEcompensated HFpEF] trial) following recent worsening heart failure (WHF) were pooled to examine treatment effect across the EF spectrum.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The PIONEER-HF and PARAGLIDE-HF trials were double-blind, randomized trials of sacubitril/valsartan vs control therapy (enalapril or valsartan, respectively). All participants in the PIONEER-HF trial and 69.5% in the PARAGLIDE-HF trial were enrolled during hospitalization for HF after stabilization. The remainder in the PARAGLIDE-HF trial were enrolled ≤30 days after a WHF event. The primary endpoint of both trials was time-averaged proportional change in N-terminal pro-B-type natriuretic peptide (NT-proBNP) from baseline through weeks 4 and 8. Adjudicated clinical endpoints were analyzed through the end of follow-up, adjusting for trial.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The pooled analysis included 1,347 patients (881 from PIONEER-HF, 466 from PARAGLIDE-HF). Baseline characteristics included median age 66 years, 36% women, 31% Black, 34% de novo HF, and median EF 30%. The reduction in NT-proBNP was 24% greater with sacubitril/valsartan vs control therapy (n = 1,130; ratio of change = 0.76; 95% CI: 0.69-0.83; P &lt; 0.0001). Cardiovascular death or hospitalization for HF was reduced by 30% with sacubitril/valsartan vs control therapy (HR: 0.70; 95% CI: 0.54-0.91; P = 0.0077). This effect was consistent across the spectrum of EF ≤60%. Sacubitril/valsartan increased symptomatic hypotension (risk ratio: 1.35; 95% CI: 1.05-1.72).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In patients stabilized after WHF, sacubitril/valsartan led to a greater reduction in plasma NT-proBNP and improved clinical outcome compared with control therapy, in particular across the spectrum of EF ≤60%. (Comparison of Sacubitril/Valsartan Versus Enalapril on Effect of NT-proBNP in Patients Stabilized From an Acute Heart Failure Episode [PIONEER-HF]; NCT02554890; Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event [HFpEF Decompensation] Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation [PARAGLIDE-HF]; NCT03988634).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38508844/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240321021056&v=2.18.0.post9+e462414">38508844</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.01.027>10.1016/j.jacc.2024.01.027</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38508844</guid>
<pubDate>Wed, 20 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>David A Morrow</dc:creator>
<dc:creator>Eric J Velazquez</dc:creator>
<dc:creator>Akshay S Desai</dc:creator>
<dc:creator>Adam D DeVore</dc:creator>
<dc:creator>Serge Lepage</dc:creator>
<dc:creator>Jeong-Gun Park</dc:creator>
<dc:creator>Kavita Sharma</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:creator>Randall C Starling</dc:creator>
<dc:creator>Jonathan H Ward</dc:creator>
<dc:creator>Kristin M Williamson</dc:creator>
<dc:creator>Shelley Zieroth</dc:creator>
<dc:creator>Adrian F Hernandez</dc:creator>
<dc:creator>Robert J Mentz</dc:creator>
<dc:creator>Eugene Braunwald</dc:creator>
<dc:date>2024-03-20</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Sacubitril/Valsartan in Patients Hospitalized With Decompensated Heart Failure</dc:title>
<dc:identifier>pmid:38508844</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.01.027</dc:identifier>
</item>
<item>
<title>Discordant High-Gradient Aortic Stenosis: Trust the Gradient</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38508843/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240321021056&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Mar 26;83(12):1120-1122. doi: 10.1016/j.jacc.2024.01.023.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38508843/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240321021056&v=2.18.0.post9+e462414">38508843</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.01.023>10.1016/j.jacc.2024.01.023</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38508843</guid>
<pubDate>Wed, 20 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Crochan J O'Sullivan</dc:creator>
<dc:creator>David O'Sullivan</dc:creator>
<dc:date>2024-03-20</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Discordant High-Gradient Aortic Stenosis: Trust the Gradient</dc:title>
<dc:identifier>pmid:38508843</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.01.023</dc:identifier>
</item>
<item>
<title>Prevalence and Outcomes of Patients With Discordant High-Gradient Aortic Stenosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38508842/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240321021056&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: DHG-AS is not uncommon. Whereas AVA >;1.0 cm² is often seen as moderate aortic stenosis, a high-pressure gradient conveys a poor prognosis, whatever the AVA and the severity of concomitant aortic regurgitation.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Mar 26;83(12):1109-1119. doi: 10.1016/j.jacc.2024.01.025.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Conflicting prognostic results have been reported in patients with discordant high-gradient aortic stenosis ([DHG-AS] the combination of a mean pressure gradient ≥40 mm Hg and an aortic valve area [AVA] >;1 cm<sup>2</sup>). Moreover, existing studies only included selected patients without concomitant aortic regurgitation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The authors assessed the prevalence and survival of patients presenting with DHG-AS in an unselected group of consecutive patients presenting to the echocardiography laboratory of a tertiary referral center.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A total of 3,547 adult patients with AVA ≤1.5 cm<sup>2</sup> and peak aortic jet velocity ≥2.5 m/s or mean gradient ≥25 mm Hg who presented between 2005 and 2015 were included. Baseline clinical and echocardiographic data, and, when available, aortic valve calcium (AVC) score were collected in an institutional database, with subsequent retrospective analysis. The primary endpoint was all-cause mortality during follow-up.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: DHG-AS was observed in 163 patients (11.6% of patients with a high gradient). After adjustment for potential confounders, overall mortality rate of patients with DHG-AS was similar to that of patients with concordant severe aortic stenosis (HR: 0.98 [95% CI: 0.66-1.44]; P = 0.91), and patients with discordant low-gradient aortic stenosis (HR: 0.85 [95% CI: 0.58-1.26]; P = 0.42), and higher than concordant moderate aortic stenosis (HR: 0.54 [95% CI: 0.36-0.81]; P = 0.003). After adjustment for aortic velocities, aortic regurgitation had no significant impact on survival. AVC was higher than in patients with concordant moderate aortic stenosis and discordant low-gradient aortic stenosis, and not significantly different from that of concordant severe aortic stenosis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: DHG-AS is not uncommon. Whereas AVA >;1.0 cm<sup>2</sup> is often seen as moderate aortic stenosis, a high-pressure gradient conveys a poor prognosis, whatever the AVA and the severity of concomitant aortic regurgitation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38508842/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240321021056&v=2.18.0.post9+e462414">38508842</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.01.025>10.1016/j.jacc.2024.01.025</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38508842</guid>
<pubDate>Wed, 20 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Philippe Unger</dc:creator>
<dc:creator>Andréanne Powers</dc:creator>
<dc:creator>Emma Le Nezet</dc:creator>
<dc:creator>Emilie Lacasse-Rioux</dc:creator>
<dc:creator>Xavier Galloo</dc:creator>
<dc:creator>Marie-Annick Clavel</dc:creator>
<dc:date>2024-03-20</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Prevalence and Outcomes of Patients With Discordant High-Gradient Aortic Stenosis</dc:title>
<dc:identifier>pmid:38508842</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.01.025</dc:identifier>
</item>
<item>
<title>JAMA Cardiology-The Year in Review, 2023</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38506885/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240321021056&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Mar 20. doi: 10.1001/jamacardio.2024.0340. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38506885/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240321021056&v=2.18.0.post9+e462414">38506885</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.0340>10.1001/jamacardio.2024.0340</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38506885</guid>
<pubDate>Wed, 20 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Robert O Bonow</dc:creator>
<dc:date>2024-03-20</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>JAMA Cardiology-The Year in Review, 2023</dc:title>
<dc:identifier>pmid:38506885</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.0340</dc:identifier>
</item>
<item>
<title>Consolidating NRMP Fellowship Matches to Enhance the Applicant Experience</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38506882/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240321021056&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Mar 20. doi: 10.1001/jamacardio.2024.0130. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38506882/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240321021056&v=2.18.0.post9+e462414">38506882</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.0130>10.1001/jamacardio.2024.0130</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38506882</guid>
<pubDate>Wed, 20 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Jeanette L Calli</dc:creator>
<dc:creator>Laurie S Curtin</dc:creator>
<dc:date>2024-03-20</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Consolidating NRMP Fellowship Matches to Enhance the Applicant Experience</dc:title>
<dc:identifier>pmid:38506882</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.0130</dc:identifier>
</item>
<item>
<title>Electrocardiographic Findings in Female Professional Basketball Athletes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38506880/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240321021056&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: This cross-sectional study provides reference ECG data for elite female basketball athletes. International criteria-defined training-related findings were common, whereas abnormal ECG findings were rare in this athlete group. These reference data may assist basketball programs and health care professionals using ECGs in screening for female athletes and may be used as a stimulus for future female-specific ECG inquiries.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Mar 20. doi: 10.1001/jamacardio.2024.0207. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Previous studies of professional basketball athletes have characterized manifestations of athletic remodeling by echocardiography and electrocardiography (ECG) in males and echocardiography in females. There is a paucity of female, basketball-specific ECG data.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To generate reference range ECG data for female professional basketball athletes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This is a cross-sectional study of ECGs performed on female professional basketball athletes. The Women's National Basketball Association mandates annual preseason ECGs and echocardiograms for each athlete and has partnered with Columbia University Irving Medical Center to annually review these studies. Data for this study were collected during preseason ECG and echocardiography cardiac screening between April and May 2022. Data analysis was performed between February and July 2023.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURE: Athlete ECGs and echocardiograms were sent to Columbia University Irving Medical Center for core lab analysis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Quantitative ECG variables were measured. ECG data were qualitatively analyzed for training-related and abnormal findings using the International Recommendations for Electrocardiographic Interpretation in Athletes. Findings from ECGs were compared with corresponding echocardiographic data.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: There were a total of 173 athletes (mean [SD] age 26.5 [4.1] years; mean [SD] height, 183.4 [9.1] cm; mean [SD] body surface area, 2.0 [0.2] m2), including 129 Black athletes (74.5%) and 40 White athletes (23.1%). By international criteria, 136 athletes (78.6%) had training-related ECG changes and 8 athletes (4.6%) had abnormal ECG findings. Among athletes with at least 1 training-related ECG finding, left ventricular structural adaptations associated with athletic remodeling were present in 64 athletes (47.1%). Increased relative wall thickness, reflecting concentric left ventricular geometry, was more prevalent in athletes with the repolarization variant demonstrating convex ST elevation combined with T-wave inversions in leads V1 to V4 (6 of 12 athletes [50.0%]) than in athletes with early repolarization (5 of 42 athletes [11.9%]) (odds ratio, 7.40; 95% CI, 1.71-32.09; P = .01). Abnormal ECG findings included T-wave inversions (3 athletes [1.7%]), Q waves (2 athletes [1.2%]), prolonged QTc interval (2 athletes [1.2%]), and frequent premature ventricular contractions (1 athlete [0.6%]).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: This cross-sectional study provides reference ECG data for elite female basketball athletes. International criteria-defined training-related findings were common, whereas abnormal ECG findings were rare in this athlete group. These reference data may assist basketball programs and health care professionals using ECGs in screening for female athletes and may be used as a stimulus for future female-specific ECG inquiries.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38506880/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240321021056&v=2.18.0.post9+e462414">38506880</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.0207>10.1001/jamacardio.2024.0207</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38506880</guid>
<pubDate>Wed, 20 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Bradley S Lander</dc:creator>
<dc:creator>Eamon Y Duffy</dc:creator>
<dc:creator>Jessica A Hennessey</dc:creator>
<dc:creator>Sonia Tolani</dc:creator>
<dc:creator>Nidhi Patel</dc:creator>
<dc:creator>Michael S Bohnen</dc:creator>
<dc:creator>Jeffrey J Hsu</dc:creator>
<dc:creator>Alfred Danielian</dc:creator>
<dc:creator>Ankit B Shah</dc:creator>
<dc:creator>Marci Goolsby</dc:creator>
<dc:creator>Matthew W Martinez</dc:creator>
<dc:creator>Dermot Phelan</dc:creator>
<dc:creator>David J Engel</dc:creator>
<dc:date>2024-03-20</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Electrocardiographic Findings in Female Professional Basketball Athletes</dc:title>
<dc:identifier>pmid:38506880</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.0207</dc:identifier>
</item>
<item>
<title>Type 2 Myocardial Infarction-Poorly Understood, Underevaluated, and Too Often Ignored</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38506815/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240321021056&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Mar 20. doi: 10.1001/jamacardio.2024.0127. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38506815/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240321021056&v=2.18.0.post9+e462414">38506815</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.0127>10.1001/jamacardio.2024.0127</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38506815</guid>
<pubDate>Wed, 20 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>James A de Lemos</dc:creator>
<dc:creator>Bertil Lindahl</dc:creator>
<dc:creator>Nicholas L Mills</dc:creator>
<dc:date>2024-03-20</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Type 2 Myocardial Infarction-Poorly Understood, Underevaluated, and Too Often Ignored</dc:title>
<dc:identifier>pmid:38506815</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.0127</dc:identifier>
</item>
<item>
<title>Ticagrelor or Clopidogrel Monotherapy vs Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: A Systematic Review and Patient-Level Meta-Analysis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38506796/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240321021056&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: This systematic review and meta-analysis found that ticagrelor monotherapy was noninferior to DAPT for all-cause death, MI, or stroke and superior for major bleeding and NACE. Clopidogrel monotherapy was similarly associated with reduced bleeding but was not noninferior to DAPT for all-cause death, MI, or stroke, largely because of risk observed in 1 trial that exclusively included East Asian patients and a hazard that was driven by an excess of noncardiovascular...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Mar 20. doi: 10.1001/jamacardio.2024.0133. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Among patients undergoing percutaneous coronary intervention (PCI), it remains unclear whether the treatment efficacy of P2Y12 inhibitor monotherapy after a short course of dual antiplatelet therapy (DAPT) depends on the type of P2Y12 inhibitor.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To assess the risks and benefits of ticagrelor monotherapy or clopidogrel monotherapy compared with standard DAPT after PCI.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DATA SOURCES: MEDLINE, Embase, TCTMD, and the European Society of Cardiology website were searched from inception to September 10, 2023, without language restriction.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">STUDY SELECTION: Included studies were randomized clinical trials comparing P2Y12 inhibitor monotherapy with DAPT on adjudicated end points in patients without indication to oral anticoagulation undergoing PCI.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DATA EXTRACTION AND SYNTHESIS: Patient-level data provided by each trial were synthesized into a pooled dataset and analyzed using a 1-step mixed-effects model. The study is reported following the Preferred Reporting Items for Systematic Review and Meta-Analyses of Individual Participant Data.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The primary objective was to determine noninferiority of ticagrelor or clopidogrel monotherapy vs DAPT on the composite of death, myocardial infarction (MI), or stroke in the per-protocol analysis with a 1.15 margin for the hazard ratio (HR). Key secondary end points were major bleeding and net adverse clinical events (NACE), including the primary end point and major bleeding.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Analyses included 6 randomized trials including 25 960 patients undergoing PCI, of whom 24 394 patients (12 403 patients receiving DAPT; 8292 patients receiving ticagrelor monotherapy; 3654 patients receiving clopidogrel monotherapy; 45 patients receiving prasugrel monotherapy) were retained in the per-protocol analysis. Trials of ticagrelor monotherapy were conducted in Asia, Europe, and North America; trials of clopidogrel monotherapy were all conducted in Asia. Ticagrelor was noninferior to DAPT for the primary end point (HR, 0.89; 95% CI, 0.74-1.06; P for noninferiority = .004), but clopidogrel was not noninferior (HR, 1.37; 95% CI, 1.01-1.87; P for noninferiority >; .99), with this finding driven by noncardiovascular death. The risk of major bleeding was lower with both ticagrelor (HR, 0.47; 95% CI, 0.36-0.62; P &lt; .001) and clopidogrel monotherapy (HR, 0.49; 95% CI, 0.30-0.81; P = .006; P for interaction = 0.88). NACE were lower with ticagrelor (HR, 0.74; 95% CI, 0.64-0.86, P &lt; .001) but not with clopidogrel monotherapy (HR, 1.00; 95% CI, 0.78-1.28; P = .99; P for interaction = .04).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: This systematic review and meta-analysis found that ticagrelor monotherapy was noninferior to DAPT for all-cause death, MI, or stroke and superior for major bleeding and NACE. Clopidogrel monotherapy was similarly associated with reduced bleeding but was not noninferior to DAPT for all-cause death, MI, or stroke, largely because of risk observed in 1 trial that exclusively included East Asian patients and a hazard that was driven by an excess of noncardiovascular death.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38506796/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240321021056&v=2.18.0.post9+e462414">38506796</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.0133>10.1001/jamacardio.2024.0133</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38506796</guid>
<pubDate>Wed, 20 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Marco Valgimigli</dc:creator>
<dc:creator>Felice Gragnano</dc:creator>
<dc:creator>Mattia Branca</dc:creator>
<dc:creator>Anna Franzone</dc:creator>
<dc:creator>Bruno R da Costa</dc:creator>
<dc:creator>Usman Baber</dc:creator>
<dc:creator>Takeshi Kimura</dc:creator>
<dc:creator>Yangsoo Jang</dc:creator>
<dc:creator>Joo-Yong Hahn</dc:creator>
<dc:creator>Qiang Zhao</dc:creator>
<dc:creator>Stephan Windecker</dc:creator>
<dc:creator>Charles M Gibson</dc:creator>
<dc:creator>Hirotoshi Watanabe</dc:creator>
<dc:creator>Byeong-Keuk Kim</dc:creator>
<dc:creator>Young Bin Song</dc:creator>
<dc:creator>Yunpeng Zhu</dc:creator>
<dc:creator>Pascal Vranckx</dc:creator>
<dc:creator>Shamir Mehta</dc:creator>
<dc:creator>Kenji Ando</dc:creator>
<dc:creator>Sung Jin Hong</dc:creator>
<dc:creator>Hyeon-Cheol Gwon</dc:creator>
<dc:creator>Patrick W Serruys</dc:creator>
<dc:creator>George D Dangas</dc:creator>
<dc:creator>Eùgene P McFadden</dc:creator>
<dc:creator>Dominick J Angiolillo</dc:creator>
<dc:creator>Dik Heg</dc:creator>
<dc:creator>Paolo Calabrò</dc:creator>
<dc:creator>Peter Jüni</dc:creator>
<dc:creator>Roxana Mehran</dc:creator>
<dc:creator>Single Versus Dual Antiplatelet Therapy (Sidney-3) Collaboration</dc:creator>
<dc:date>2024-03-20</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Ticagrelor or Clopidogrel Monotherapy vs Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: A Systematic Review and Patient-Level Meta-Analysis</dc:title>
<dc:identifier>pmid:38506796</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.0133</dc:identifier>
</item>
<item>
<title>AKAP12 Upregulation Associates With PDE8A to Accelerate Cardiac Dysfunction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38506047/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240321021056&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: AKAP12 upregulation in cardiac tissue is associated with accelerated cardiac dysfunction through the AKAP12-PDE8 axis.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Mar 20. doi: 10.1161/CIRCRESAHA.123.323655. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: In heart failure, signaling downstream the β2-adrenergic receptor is critical. Sympathetic stimulation of β2-adrenergic receptor alters cAMP (cyclic adenosine 3',5'-monophosphate) and triggers PKA (protein kinase A)-dependent phosphorylation of proteins that regulate cardiac function. cAMP levels are regulated in part by PDEs (phosphodiesterases). Several AKAPs (A kinase anchoring proteins) regulate cardiac function and are proposed as targets for precise pharmacology. AKAP12 is expressed in the heart and has been reported to directly bind β2-adrenergic receptor, PKA, and PDE4D. However, its roles in cardiac function are unclear.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: cAMP accumulation in real time downstream of the β2-adrenergic receptor was detected for 60 minutes in live cells using the luciferase-based biosensor (GloSensor) in AC16 human-derived cardiomyocyte cell lines overexpressing AKAP12 versus controls. Cardiomyocyte intracellular calcium and contractility were studied in adult primary cardiomyocytes from male and female mice overexpressing cardiac AKAP12 (AKAP12<sup>OX</sup>) and wild-type littermates postacute treatment with 100-nM isoproterenol. Systolic cardiac function was assessed in mice after 14 days of subcutaneous isoproterenol administration (60 mg/kg per day). AKAP12 gene and protein expression levels were evaluated in left ventricular samples from patients with end-stage heart failure.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: AKAP12 upregulation significantly reduced total intracellular cAMP levels in AC16 cells through PDE8. Adult primary cardiomyocytes from AKAP12<sup>OX</sup> mice had significantly reduced contractility and impaired calcium handling in response to isoproterenol, which was reversed in the presence of the selective PDE8 inhibitor (PF-04957325). AKAP12<sup>OX</sup> mice had deteriorated systolic cardiac function and enlarged left ventricles. Patients with end-stage heart failure had upregulated gene and protein levels of AKAP12.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: AKAP12 upregulation in cardiac tissue is associated with accelerated cardiac dysfunction through the AKAP12-PDE8 axis.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38506047/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240321021056&v=2.18.0.post9+e462414">38506047</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323655>10.1161/CIRCRESAHA.123.323655</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38506047</guid>
<pubDate>Wed, 20 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Hanan Qasim</dc:creator>
<dc:creator>Mehrdad Rajaei</dc:creator>
<dc:creator>Ying Xu</dc:creator>
<dc:creator>Arfaxad Reyes-Alcaraz</dc:creator>
<dc:creator>Hala Y Abdelnasser</dc:creator>
<dc:creator>M David Stewart</dc:creator>
<dc:creator>Satadru K Lahiri</dc:creator>
<dc:creator>Xander H T Wehrens</dc:creator>
<dc:creator>Bradley K McConnell</dc:creator>
<dc:date>2024-03-20</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>AKAP12 Upregulation Associates With PDE8A to Accelerate Cardiac Dysfunction</dc:title>
<dc:identifier>pmid:38506047</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323655</dc:identifier>
</item>
<item>
<title>Virus-Induced Acute Respiratory Distress Syndrome Causes Cardiomyopathy Through Eliciting Inflammatory Responses in the Heart</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38506045/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240321021056&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Our data suggest that viral ARDS promotes cardiac inflammation by expanding the CCR2^(+) macrophage subset, and the associated cardiac phenotypes in mice can be elicited by activating the host immune system even without viral presence in the heart.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Mar 20. doi: 10.1161/CIRCULATIONAHA.123.066433. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Viral infections can cause acute respiratory distress syndrome (ARDS), systemic inflammation, and secondary cardiovascular complications. Lung macrophage subsets change during ARDS, but the role of heart macrophages in cardiac injury during viral ARDS remains unknown. Here we investigate how immune signals typical for viral ARDS affect cardiac macrophage subsets, cardiovascular health, and systemic inflammation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We assessed cardiac macrophage subsets using immunofluorescence histology of autopsy specimens from 21 patients with COVID-19 with SARS-CoV-2-associated ARDS and 33 patients who died from other causes. In mice, we compared cardiac immune cell dynamics after SARS-CoV-2 infection with ARDS induced by intratracheal instillation of Toll-like receptor ligands and an ACE2 (angiotensin-converting enzyme 2) inhibitor.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In humans, SARS-CoV-2 increased total cardiac macrophage counts and led to a higher proportion of CCR2<sup>+</sup> (C-C chemokine receptor type 2 positive) macrophages. In mice, SARS-CoV-2 and virus-free lung injury triggered profound remodeling of cardiac resident macrophages, recapitulating the clinical expansion of CCR2<sup>+</sup> macrophages. Treating mice exposed to virus-like ARDS with a tumor necrosis factor α-neutralizing antibody reduced cardiac monocytes and inflammatory MHCII<sup>lo</sup> CCR2<sup>+</sup> macrophages while also preserving cardiac function. Virus-like ARDS elevated mortality in mice with pre-existing heart failure.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our data suggest that viral ARDS promotes cardiac inflammation by expanding the CCR2<sup>+</sup> macrophage subset, and the associated cardiac phenotypes in mice can be elicited by activating the host immune system even without viral presence in the heart.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38506045/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240321021056&v=2.18.0.post9+e462414">38506045</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066433>10.1161/CIRCULATIONAHA.123.066433</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38506045</guid>
<pubDate>Wed, 20 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Jana Grune</dc:creator>
<dc:creator>Geetika Bajpai</dc:creator>
<dc:creator>Pervin Tülin Ocak</dc:creator>
<dc:creator>Eva Kaufmann</dc:creator>
<dc:creator>Kyle Mentkowksi</dc:creator>
<dc:creator>Steffen Pabel</dc:creator>
<dc:creator>Nina Kumowski</dc:creator>
<dc:creator>Fadi E Pulous</dc:creator>
<dc:creator>Kim A Tran</dc:creator>
<dc:creator>David Rohde</dc:creator>
<dc:creator>Shuang Zhang</dc:creator>
<dc:creator>Yoshiko Iwamoto</dc:creator>
<dc:creator>Gregory R Wojtkiewicz</dc:creator>
<dc:creator>Claudio Vinegoni</dc:creator>
<dc:creator>Ursula Green</dc:creator>
<dc:creator>Filip K Swirski</dc:creator>
<dc:creator>James R Stone</dc:creator>
<dc:creator>Jochen K Lennerz</dc:creator>
<dc:creator>Maziar Divangahi</dc:creator>
<dc:creator>Maarten Hulsmans</dc:creator>
<dc:creator>Matthias Nahrendorf</dc:creator>
<dc:date>2024-03-20</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Virus-Induced Acute Respiratory Distress Syndrome Causes Cardiomyopathy Through Eliciting Inflammatory Responses in the Heart</dc:title>
<dc:identifier>pmid:38506045</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066433</dc:identifier>
</item>
<item>
<title>Deep learning to detect left ventricular structural abnormalities in chest X-rays</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38503537/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240321021056&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Deep learning analysis of CXRs can accurately detect the presence of certain structural abnormalities and may be useful in early identification of patients with LV hypertrophy and dilation. As a resource to promote further innovation, 71 589 CXRs with adjoining echocardiographic labels have been made publicly available.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 20:ehad782. doi: 10.1093/eurheartj/ehad782. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Early identification of cardiac structural abnormalities indicative of heart failure is crucial to improving patient outcomes. Chest X-rays (CXRs) are routinely conducted on a broad population of patients, presenting an opportunity to build scalable screening tools for structural abnormalities indicative of Stage B or worse heart failure with deep learning methods. In this study, a model was developed to identify severe left ventricular hypertrophy (SLVH) and dilated left ventricle (DLV) using CXRs.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A total of 71 589 unique CXRs from 24 689 different patients completed within 1 year of echocardiograms were identified. Labels for SLVH, DLV, and a composite label indicating the presence of either were extracted from echocardiograms. A deep learning model was developed and evaluated using area under the receiver operating characteristic curve (AUROC). Performance was additionally validated on 8003 CXRs from an external site and compared against visual assessment by 15 board-certified radiologists.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The model yielded an AUROC of 0.79 (0.76-0.81) for SLVH, 0.80 (0.77-0.84) for DLV, and 0.80 (0.78-0.83) for the composite label, with similar performance on an external data set. The model outperformed all 15 individual radiologists for predicting the composite label and achieved a sensitivity of 71% vs. 66% against the consensus vote across all radiologists at a fixed specificity of 73%.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Deep learning analysis of CXRs can accurately detect the presence of certain structural abnormalities and may be useful in early identification of patients with LV hypertrophy and dilation. As a resource to promote further innovation, 71 589 CXRs with adjoining echocardiographic labels have been made publicly available.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38503537/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240321021056&v=2.18.0.post9+e462414">38503537</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad782>10.1093/eurheartj/ehad782</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38503537</guid>
<pubDate>Tue, 19 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Shreyas Bhave</dc:creator>
<dc:creator>Victor Rodriguez</dc:creator>
<dc:creator>Timothy Poterucha</dc:creator>
<dc:creator>Simukayi Mutasa</dc:creator>
<dc:creator>Dwight Aberle</dc:creator>
<dc:creator>Kathleen M Capaccione</dc:creator>
<dc:creator>Yibo Chen</dc:creator>
<dc:creator>Belinda Dsouza</dc:creator>
<dc:creator>Shifali Dumeer</dc:creator>
<dc:creator>Jonathan Goldstein</dc:creator>
<dc:creator>Aaron Hodes</dc:creator>
<dc:creator>Jay Leb</dc:creator>
<dc:creator>Matthew Lungren</dc:creator>
<dc:creator>Mitchell Miller</dc:creator>
<dc:creator>David Monoky</dc:creator>
<dc:creator>Benjamin Navot</dc:creator>
<dc:creator>Kapil Wattamwar</dc:creator>
<dc:creator>Anoop Wattamwar</dc:creator>
<dc:creator>Kevin Clerkin</dc:creator>
<dc:creator>David Ouyang</dc:creator>
<dc:creator>Euan Ashley</dc:creator>
<dc:creator>Veli K Topkara</dc:creator>
<dc:creator>Mathew Maurer</dc:creator>
<dc:creator>Andrew J Einstein</dc:creator>
<dc:creator>Nir Uriel</dc:creator>
<dc:creator>Shunichi Homma</dc:creator>
<dc:creator>Allan Schwartz</dc:creator>
<dc:creator>Diego Jaramillo</dc:creator>
<dc:creator>Adler J Perotte</dc:creator>
<dc:creator>Pierre Elias</dc:creator>
<dc:date>2024-03-19</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Deep learning to detect left ventricular structural abnormalities in chest X-rays</dc:title>
<dc:identifier>pmid:38503537</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad782</dc:identifier>
</item>
<item>
<title>RNA damage compartmentalization by DHX9 stress granules</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38503283/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240321021056&amp;v=2.18.0.post9+e462414
      <description>Biomolecules incur damage during stress conditions, and damage partitioning represents a vital survival strategy for cells. Here, we identified a distinct stress granule (SG), marked by dsRNA helicase DHX9, which compartmentalizes ultraviolet (UV)-induced RNA, but not DNA, damage. Our FANCI technology revealed that DHX9 SGs are enriched in damaged intron RNA, in contrast to classical SGs that are composed of mature mRNA. UV exposure causes RNA crosslinking damage, impedes intron splicing and...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Mar 7:S0092-8674(24)00231-9. doi: 10.1016/j.cell.2024.02.028. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Biomolecules incur damage during stress conditions, and damage partitioning represents a vital survival strategy for cells. Here, we identified a distinct stress granule (SG), marked by dsRNA helicase DHX9, which compartmentalizes ultraviolet (UV)-induced RNA, but not DNA, damage. Our FANCI technology revealed that DHX9 SGs are enriched in damaged intron RNA, in contrast to classical SGs that are composed of mature mRNA. UV exposure causes RNA crosslinking damage, impedes intron splicing and decay, and triggers DHX9 SGs within daughter cells. DHX9 SGs promote cell survival and induce dsRNA-related immune response and translation shutdown, differentiating them from classical SGs that assemble downstream of translation arrest. DHX9 modulates dsRNA abundance in the DHX9 SGs and promotes cell viability. Autophagy receptor p62 is activated and important for DHX9 SG disassembly. Our findings establish non-canonical DHX9 SGs as a dedicated non-membrane-bound cytoplasmic compartment that safeguards daughter cells from parental RNA damage.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38503283/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240321021056&v=2.18.0.post9+e462414">38503283</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.02.028>10.1016/j.cell.2024.02.028</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38503283</guid>
<pubDate>Tue, 19 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Yilong Zhou</dc:creator>
<dc:creator>Amol Panhale</dc:creator>
<dc:creator>Maria Shvedunova</dc:creator>
<dc:creator>Mirela Balan</dc:creator>
<dc:creator>Alejandro Gomez-Auli</dc:creator>
<dc:creator>Herbert Holz</dc:creator>
<dc:creator>Janine Seyfferth</dc:creator>
<dc:creator>Martin Helmstädter</dc:creator>
<dc:creator>Séverine Kayser</dc:creator>
<dc:creator>Yuling Zhao</dc:creator>
<dc:creator>Niyazi Umut Erdogdu</dc:creator>
<dc:creator>Iga Grzadzielewska</dc:creator>
<dc:creator>Gerhard Mittler</dc:creator>
<dc:creator>Thomas Manke</dc:creator>
<dc:creator>Asifa Akhtar</dc:creator>
<dc:date>2024-03-19</dc:date>
<dc:source>Cell</dc:source>
<dc:title>RNA damage compartmentalization by DHX9 stress granules</dc:title>
<dc:identifier>pmid:38503283</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.02.028</dc:identifier>
</item>





























</channel>
</rss>